- Xarelto Lawsuits Filed at Increasing Rate
- September 24, 2015
- Law Firm: Waters Kraus LLP - Dallas Office
- Recent U.S. Judicial Panel on Multidistrict Litigation statistics reveal a steady rise in the number of Xarelto lawsuits filed in federal court. Between May 15 and June 15, the increased filings were particularly high. Xarelto bleeding complications have been a problem for thousands of Americans who switched to Xarelto from the former anticoagulant of choice, warfarin (Coumadin).
In December 2014, Xarelto lawsuits filed in federal court were consolidated for pretrial litigation before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana. The MDL is called In re: Xarelto (rivaroxaban) Products Liability Litigation, No. 2592.
The number of cases filed is 552, which reportedly represents a 27.2 percent increase.
Xarelto MDL Moving Toward Trial Date for First Test Case
Both sides in the Xarelto litigation are now working on schedules for depositions and other pre-trial discovery. The first bellwether trial has a tentative trial date of August 1, 2016. The court has adopted the use of new forms, including the pared-down “Joint Complaint” and “Short Form Complaint” that should help to streamline the Xarelto lawsuit process.
Defendants in the Xarelto bleeding lawsuits include Janssen Research & Development, Johnson & Johnson and Bayer Healthcare Pharmaceuticals. Xarelto has been shown to cause uncontrollable bleeding and hemorrhagic stroke in emergency situations. Patients taking warfarin (Coumadin) also may experience drug injury such as sudden bleeding, but it can be stopped with an infusion of vitamin K. There is no antidote for uncontrollable bleeding caused by Xarelto.